Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

OSHIH

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

Standard Dose
0.02MG;1MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview OSHIH is listed in Drugs@FDA under application 216558 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ETHINYL ESTRADIOL; NORETHINDRONE ACETATE Form and strength TABLET;ORAL - 0.02MG;1MG Sponsor AUROBINDO PHARMA Submission history Latest submission status date: 2023-12-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview OSHIH is listed in Drugs@FDA under application 216558 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ETHINYL ESTRADIOL; NORETHINDRONE ACETATE Form and strength TABLET;ORAL - 0.02MG;1MG Sponsor AUROBINDO PHARMA Submission history Latest submission status date: 2023-12-06 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
OSHIH (ETHINYL ESTRADIOL; NORETHINDRONE ACETATE) | Drug Monograph | MedicHelpline